Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes
about
sameAs
Chemical structure and pharmacokinetics of novel quinolone agents represented by avarofloxacin, delafloxacin, finafloxacin, zabofloxacin and nemonoxacinBrain tumor delineation enhanced by moxifloxacin-based two-photon/CARS combined microscopyIDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults.Moxifloxacin safety: an analysis of 14 years of clinical data.Risks associated with the therapeutic use of fluoroquinolones.Treatment of community-acquired pneumonia with moxifloxacin: a meta-analysis of randomized controlled trials.Efficacy and safety of moxifloxacin in acute exacerbations of chronic bronchitis: a prospective, multicenter, observational study (AVANTI)Rickettsia typhi infection with interstitial pneumonia in a traveler treated with moxifloxacin.Risk of acute liver injury associated with the use of moxifloxacin and other oral antimicrobials: a retrospective, population-based cohort study.Liver injury in the elderly due to fluoroquinolones: should these drugs be avoided?Fluoroquinolone therapy and idiosyncratic acute liver injury: a population-based study.Update on the cardiac safety of moxifloxacin.Hypersensitivity to fluoroquinolones: The expression of basophil activation markers depends on the clinical entity and the culprit fluoroquinolone.Clinical and histopathologic features of fluoroquinolone-induced liver injury.Changes in ventricular repolarization duration during typical daily emotion in patients with Long QT syndrome.Efficacy and safety of moxifloxacin in acute exacerbations of chronic bronchitis and COPD: a systematic review and meta-analysisImmediate hypersensitivity to moxifloxacin with tolerance to ciprofloxacin: report of three cases and review of the literature.Drug-induced photosensitivity: culprit drugs, management and prevention.Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases.Fluoroquinolone-induced liver injury: three new cases and a review of the literature.The use of moxifloxacin for acute exacerbations of chronic obstructive pulmonary disease and chronic bronchitis.Current treatment for nocardia infections.Renaissance of antibiotics against difficult infections: Focus on oritavancin and new ketolides and quinolones.Safety issues and drug-drug interactions with commonly used quinolones.The role of solithromycin in the management of bacterial community-acquired pneumonia.Effect of norfloxacin and moxifloxacin on melanin synthesis and antioxidant enzymes activity in normal human melanocytes.Orally administered moxifloxacin prolongs QTc in healthy Chinese volunteers: a randomized, single-blind, crossover study.New treatment options for lower respiratory tract infections.In Vitro Activity of AZD0914, a Novel Bacterial DNA Gyrase/Topoisomerase IV Inhibitor, against Clinically Relevant Gram-Positive and Fastidious Gram-Negative Pathogens.Population pharmacokinetic modeling of the unbound levofloxacin concentrations in rat plasma and prostate tissue measured by microdialysis.Ofloxacin-induced toxic epidermal necrolysis.Fluoroquinolone photodegradation influences specific basophil activation.Supra-therapeutic doses of roflumilast have no effect on cardiac repolarization in healthy subjects.Safety of Delafloxacin: Focus on Adverse Events of Special InterestIdiosyncratic Drug-Induced Liver Injury Due to Ciprofloxacin: A Report of Two Cases and Review of the Literature
P2860
Q26746616-FCA6F36B-DC3E-47F1-ADF2-D1E23BE41A1AQ33917705-E2482F3D-357B-4A45-BB70-63F49A1D7C01Q34262840-1081531C-C9CF-41AF-9741-E7BF0BCD4086Q34310568-91AD4385-20D3-4B2A-80FF-A23839E3BF44Q34343391-443C6B07-274C-4107-B2C2-409CB70BF98BQ34488843-31D02D74-546E-4760-9E12-25A9B50C698EQ34560033-6A8CCD19-87AC-4055-BCEA-CA642E4E0F33Q34596410-17B52696-8E74-4201-82B0-4125441ADADCQ34658795-96AE2FDA-31F6-4466-B174-B03653E695CEQ36315118-64BF28D1-5F6A-4519-9201-526894EA5FB3Q36315127-81CE0683-B98A-472B-BA7B-9A84C6A5E519Q36345861-5FED319E-083D-40FF-963B-915FCCA611E1Q37003616-26ECF8BC-8536-44A7-BC2E-FAD977B2A1D1Q37031426-B02DF930-4505-44D5-BE13-3D239CD10C6BQ37561723-C1A878F6-3517-49B1-B30F-5DEC32824B3BQ37629535-E389EBCC-4B92-49C5-9939-0CAC24BEE0F1Q37710230-28D76C0D-C700-40B4-8721-3E521F801A0EQ37924276-82F84F01-0D39-4713-AD4C-1DE6AF5C95FEQ37959271-AC465410-2C2E-45C2-A6EB-C78534E89B84Q37975927-7625C680-2628-43E1-A3E9-180E65C188B8Q38056764-354F0BE2-F0BE-40CD-9A50-68265B4E1860Q38149157-398BFD87-2D11-4BF7-9259-0E324ADE4F1EQ38233471-F656D718-4681-4FF9-B4D9-ADEA3BD80564Q38271318-0EDF2330-1103-47BC-BFA1-1577B2DC4E05Q38723961-64904E74-1214-4430-A6F3-B754676087A1Q38936976-5E717D88-E228-4104-9FD0-2DCA62DD8BB1Q39304680-1E9EBBEA-092F-42CF-AB40-47F422A1CA44Q40111519-925FC88E-5966-4845-8A91-BC82BB05C9B5Q41098625-39673A4C-9576-4A5D-9632-72D313AA0BA7Q41907641-E082C963-CD13-4899-907B-C8DF6841D333Q42794077-8021EDA9-D277-4D51-9FA4-5A48FB514530Q45053090-ABEFBBDB-7049-4A9F-B454-CF7D67B62361Q51568037-288C4719-18D1-4F56-B479-3C569E7F3413Q57822396-9933DA21-A347-4DA6-ADE3-5EF8CA11E4BEQ58795536-31A75DCB-382E-4503-8706-9EDC0E90FF5A
P2860
Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes
description
2009 nî lūn-bûn
@nan
2009 թուականին հրատարակուած գիտական յօդուած
@hyw
2009 թվականին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Safety profile of the respirat ...... nd other antibacterial classes
@ast
Safety profile of the respirat ...... nd other antibacterial classes
@en
Safety profile of the respirat ...... nd other antibacterial classes
@nl
type
label
Safety profile of the respirat ...... nd other antibacterial classes
@ast
Safety profile of the respirat ...... nd other antibacterial classes
@en
Safety profile of the respirat ...... nd other antibacterial classes
@nl
altLabel
Safety Profile of the Respiratory Fluoroquinolone Moxifloxacin
@en
prefLabel
Safety profile of the respirat ...... nd other antibacterial classes
@ast
Safety profile of the respirat ...... nd other antibacterial classes
@en
Safety profile of the respirat ...... nd other antibacterial classes
@nl
P2860
P3181
P1433
P1476
Safety Profile of the Respiratory Fluoroquinolone Moxifloxacin
@en
Safety profile of the respirat ...... nd other antibacterial classes
@en
P2093
Paul M. Tulkens
P2860
P3181
P356
10.2165/00002018-200932050-00001
P407
P577
2009-01-01T00:00:00Z
P6179
1000910883